CAJ | 학술논문

目的：探讨恩替卡韦治疗慢性乙型肝炎的临床疗效。方法：选择我院2011~2013年收治的70例慢性乙型肝炎患者的资料，将患者随机分为观察组及对照组，各35例，观察组患者应用恩替卡韦治疗，对照组患者应用拉米夫定治疗，用药时间至少为40周，应用聚合酶链反应定量法检测患者治疗前及治疗后10周、20周、30周、40周病毒量，比较两组患者治疗前、后肝功能指标变化情况，同时记录不良反应情况，监测药物安全性。结果：经过40周干预，两组患者HBV-DNA水平均出现下降，观察组患者下降更为明显，比较差异有统计学意义(P<0.05)；观察组患者谷丙转氨酶(ALT)复常率高于对照组，比较差异有统计学意义(P<0.05)；两组患者不良事件发生率相当，无明显差异，无统计学意义(P>0.05)。结论：恩替卡韦治疗慢性乙型肝炎患者，抑制病毒复制及改善肝脏功能方面均有良好疗效，值得在临床推广。
목적：탐토은체잡위치료만성을형간염적림상료효。방법：선택아원2011~2013년수치적70례만성을형간염환자적자료，장환자수궤분위관찰조급대조조，각35례，관찰조환자응용은체잡위치료，대조조환자응용랍미부정치료，용약시간지소위40주，응용취합매련반응정량법검측환자치료전급치료후10주、20주、30주、40주병독량，비교량조환자치료전、후간공능지표변화정황，동시기록불량반응정황，감측약물안전성。결과：경과40주간예，량조환자HBV-DNA수평균출현하강，관찰조환자하강경위명현，비교차이유통계학의의(P<0.05)；관찰조환자곡병전안매(ALT)복상솔고우대조조，비교차이유통계학의의(P<0.05)；량조환자불량사건발생솔상당，무명현차이，무통계학의의(P>0.05)。결론：은체잡위치료만성을형간염환자，억제병독복제급개선간장공능방면균유량호료효，치득재림상추엄。
To evaluate the clinical efficacy of entecavir treatment of chronic hepatitis B.Methods:Data of 70 cases of patients with chronic hepatitis B Hospital from 2011 to 2013 treated in our hospital were collected.All the patients were randomly divided into observation group and control group and each group contained 35 cases.Patients in the observation group received entecavir treatment,while patients in the control group received lamivudine treatment.All the patients received medication for at least 40 weeks before the quantitative polymerase chain reaction method was applied to detect the HBV load of each patient before and after treatment at 10 weeks,20 weeks,30 weeks and 40 weeks.The liver function changes of patients in the two groups were compared before and after treatment,while adverse drug reactions were recorded to monitor drug safety.Results:Patients in both two groups were demonstrated declining HBV-DNA levels after 40 weeks intervention,and in the observation group the levels were decreased more significantly.The difference was statistically significant (P<0.05).Alanine aminotransferase (ALT) normalization rates in the observation group were significantly higher than those in the control group (P<0.05).The incidence of adverse drug events was equal in both two groups and no significant difference was observed (P>0.05).Conclusion:Entecavir treatment of chronic hepatitis B patients can inhibit viral replication and improve liver function.It is worthy of clinical promotion.